{"id":"W4221038606","doi":"10.1158/1538-7445.sabcs21-pd10-05","title":"Abstract PD10-05: Activity of atezolizumab (atezo) plus paclitaxel (pac) in metastatic triple-negative breast cancer (mTNBC) according to Burstein molecular subtype: Analysis of the IMpassion131 trial","year":2022,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Medicine; Oncology; Internal medicine; Triple-negative breast cancer; Taxane; Clinical endpoint; Breast cancer; Population; Progression-free survival; Paclitaxel; Adjuvant; Cancer; Randomized controlled trial; Chemotherapy; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003298183,0.0006466632,0.001016452,0.0002345478,0.0002400919,0.001265806,0.000788527,0.0008482501,0.003631431],"category_scores_gemma":[0.002611012,0.0003421566,0.00244997,0.0004445087,0.0007280196,0.0006781779,0.0005865093,0.003165913,0.0007734395],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001121925,"about_ca_system_score_gemma":0.0009417327,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008054379,"about_ca_topic_score_gemma":0.002687196,"domain_scores_codex":[0.9987726,0.0006664651,0.00009857929,0.0001998994,0.0001506309,0.0001118617],"domain_scores_gemma":[0.9983981,0.0004369474,0.0004085853,0.0001854232,0.0001166944,0.0004542502],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8846716,0.006875778,0.02367474,0.0008858707,0.004200871,0.00004760498,0.0001395566,0.00136518,0.009840334,0.0003402749,0.004090556,0.06386762],"study_design_scores_gemma":[0.5553347,0.2880105,0.1268471,0.0002751249,0.007149977,0.000554788,0.0002082093,0.003219211,0.005639599,0.001026976,0.01161634,0.0001174841],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9883294,0.003590355,0.0003288971,0.0006862262,0.0001147015,0.0007663405,0.00326762,0.00003295035,0.002883432],"genre_scores_gemma":[0.9866477,0.001169397,0.0008863909,0.001146075,0.0001415436,0.0007069994,0.007688879,0.00002087879,0.001592245],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003631431,"threshold_uncertainty_score":0.01744264,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08240046586389813,"score_gpt":0.4384546055163097,"score_spread":0.3560541396524116,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}